New Research on Cesium Blu Presented at ASTRO

With over ten years of data on Cesium Blu, researchers continue to study its value in powering modern brachytherapy.  ASTRO 2020 showcased multiple new e-posters and papers that can now be easily accessed online.

 

A Matched Pair Analysis Of Clinical Outcomes After Intracavitary Cesium-131 Brachytherapy Versus Stereotactic Radiosurgery For Resected Brain Metastases

Conclusion: Patients with brain metastases and GTR were more likely to achieve LC with Cs-131 brachytherapy as compared with SRS. These retrospective data provide evidence for Cs-131 to reduce LR for BM following GTR, with minimal toxicity, and would support a prospective, randomized study.

Read the Full Text

 

Report of a Large Cohort of Intermediate-Risk Prostate Cancer Patients Treated with Cs-131 Brachytherapy

Conclusion: The FIR subgroup is a distinct entity from the UIR subgroup with excellent outcomes when treated with Cs-131 PB alone. UIR patients have excellent outcomes with combined EBRT + PB. The majority of UIR patients do not require ADT, though the group that would benefit still needs to be defined.

Read the Full Text

 

Cs-131 Intracavitary Brachytherapy as an Adjunct to Maximal Safe Resection for Locally Recurrent High-Grade Glioma

Conclusion: Cs-131 seed implantation using a bioabsorbable collagen matrix delivery device is a feasible method of achieving dose-escalated re-irradiation starting at time of implantation.

Read the Full Text

 

Brachytherapy Mesh for Margin Enhancement after Resection of Recurrent Malignancy

Conclusion: IORT via brachytherapy mesh placement at time of resection for high-risk malignancies appears feasible and effective across multiple sites and histologies. Locoregional disease control rates after R1 resections were adequate and treatment-related toxicities were minimal.

Read the Full Text

 

The Effect of Positive Biopsy Cores on the Prognosis of Patients with Intermediate Risk Prostate Cancer Treated with Cs-131 Prostate Brachytherapy

Conclusion: In patients treated with Cs-131 PB, those with GG2 disease have an excellent prognosis, regardless of % of biopsy cores positive for PC. Patients with GG3 and < 50% of cores positive also have an excellent prognosis, while patients with GG3 and >50% of cores positive seem to have a worse prognosis and likely would benefit from more aggressive treatment, such as trimodality therapy.

Read the Full Text

 

We look forward to seeing everyone at the annual ASTRO meeting next October.